Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enovis Corporation filings document the formal disclosures of a public medical technology company with Reconstructive and Prevention & Recovery operations. Recent Form 8-K reports cover quarterly and annual results, furnished earnings releases, conference presentation materials and Regulation FD disclosures tied to management presentations.
The filing record also includes proxy materials for annual meeting governance, board and executive compensation matters, executive transition disclosures, and material financing agreements. Enovis filings describe credit facilities, leverage covenants, guarantor arrangements, senior unsecured convertible notes references, financial condition, segment performance and related risk and governance subjects.
Enovis Corporation reported a planned leadership transition in its human resources function. Senior Vice President and Chief Human Resources Officer Patricia A. Lang informed the board she intends to retire from her current role on April 3, 2026, then serve in an advisory position until her full retirement from the company on April 3, 2027.
Enovis expects to appoint Laura Singleton, currently Vice President of Human Resources for the Reconstructive segment, as the new Senior Vice President and Chief Human Resources Officer effective April 3, 2026. Singleton joined Enovis in 2019 through its acquisition of DJO Global and has held multiple senior HR roles, and she holds a B.A. in history from Texas State University.
The company and Ms. Lang entered into a retirement transition agreement covering the period from April 3, 2026 through April 3, 2027. During this time, she will receive her current base salary for six months, after which it may be reduced by up to 50% for the remainder of the transition period, while remaining eligible for existing benefit plans and the annual incentive plan based on her actual base pay. The full agreement will be filed with Enovis’s Form 10-K for the year ended December 31, 2025.
Enovis Corp insider, a former Executive Vice President of Strategy & Business Development, reported multiple stock sales in a Form 4 filing. On December 9, 2025, the reporting person sold 666 shares of Enovis common stock at $27.21 per share in a direct transaction and held 160,449 shares directly afterward, plus 932 shares through a 401(k) plan. On the same date, three separate sales of 333 shares each were made at prices around $27.20 per share through trusts for the reporting person's daughter and son, leaving those trusts with no remaining shares.
Enovis Corporation entered into a Third Amendment to its existing credit agreement, updating the terms of its main debt facilities. The amended agreement provides a revolving credit facility of up to $1.1 billion and a $700.0 million term loan facility, and extends the maturity date for both to December 8, 2030, with an earlier maturity if, 91 days before that date, the company’s liquidity is less than 125% of the principal on its senior unsecured convertible notes.
The amendment keeps the required maximum Senior Secured Leverage Ratio at 3.50 to 1.00, but allows a temporary higher ratio after one or more acquisitions with aggregate consideration of $300.0 million or more, down from the prior $500.0 million threshold. It also increases the amount of unrestricted cash that can offset debt in leverage calculations to $400.0 million, from $150.0 million, reduces interest margins when the Total Leverage Ratio is below 1.50 to 1.00, and raises the cap on consideration for certain permitted acquisitions from $150.0 million to $200.0 million.
As of December 8, 2025, after applying the new terms, Enovis used part of the term loan proceeds to repay about $335.0 million of revolving borrowings, leaving $167.0 million outstanding under the revolving facility and $700.0 million outstanding under the term loan facility. Additional banks, including Truist Bank, DNB Capital LLC and Sumitomo Mitsui Banking Corporation, joined as lenders under the amended agreement.
Enovis Corp reported an insider stock purchase by a company officer. On 11/25/2025, the officer bought 2,468 shares of Enovis common stock at a price of $30.32 per share in an open-market transaction coded as a purchase. Following this trade, the officer directly owns 12,302 shares of Enovis common stock. The filing was made on Form 4 for one reporting person and signed by attorney-in-fact Brian P. Hanigan.
Enovis (ENOV) reported Q3 2025 results with net sales of $548.9 million, up from $505.2 million a year ago, but recorded a non-cash goodwill impairment of $548.4 million. The charge drove an operating loss of $558.5 million and a net loss of $570.9 million, or $9.99 per share from continuing operations.
Both segments grew: Prevention & Recovery sales were $290.9 million and Reconstructive sales were $258.0 million. Adjusted EBITDA was $94.8 million versus $90.2 million, reflecting underlying operating performance despite elevated non-cash items.
The company approved and closed the sale of its Dr Comfort Footcare Solutions line to Promus Equity Partners for up to $60 million in cash, including $45 million upfront and up to $15 million contingent on milestones. Enovis recognized a $7.6 million loss on assets held for sale in connection with the transaction. Year-to-date, cash from operations was $128.7 million. Total debt was $1.36 billion, with $355 million available on the Revolver and a 5.75% weighted-average borrowing rate. Shares outstanding were 57.19 million as of October 31, 2025.
Enovis Corporation filed an 8-K announcing it issued a press release with financial results for the third quarter ended October 3, 2025.
The company scheduled a conference call for 8:30 a.m. Eastern on November 6, 2025 to discuss these results. The press release is included as Exhibit 99.1.
Enovis director Angela S. Lalor reported acquiring 742 shares of Enovis Corp (ENOV) on 09/30/2025 at a reported price of $0.00, increasing her direct beneficial ownership to 21,295 shares. The Form 4 shows the filing was signed by attorney-in-fact Brian P. Hanigan on 10/01/2025. The filing identifies Lalor as a director and indicates this is a single-person Form 4 filing. No derivative transactions or additional details are reported.
Damien McDonald, listed as Chief Executive Officer and Director of Enovis Corporation (ENOV), purchased 6,457 shares of Enovis common stock on 09/11/2025. The reported weighted-average price per share was $30.97, with transaction prices ranging from $30.73 to $31.16. After the purchase, the reporting person beneficially owned 102,753 shares. The Form 4 was signed on behalf of Mr. McDonald by attorney-in-fact Brian P. Hanigan.
Insider purchase by Enovis executive: Tandy Bradley J, SVP and Chief Legal Officer of Enovis Corporation (ENOV), reported purchasing 3,200 shares of Enovis common stock on 08/22/2025 at a price of $31.41 per share. After the transaction, Mr. Bradley beneficially owned 43,515 shares. The Form 4 was signed via attorney-in-fact on 08/25/2025.
Enovis insider purchase disclosed on Form 4. Philip Benjamin Berry, SVP and Chief Financial Officer, purchased 2,500 shares of Enovis Corporation (ticker ENOV) on 08/20/2025 at a price of $29.71 per share. After the transaction, Mr. Berry beneficially owned 116,729 shares. The Form 4 was filed as a single reporting person filing and was signed by attorney-in-fact Brian P. Hanigan on 08/20/2025.